Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Gilead Sciences Stock Sees Relative Strength Rating Jump To 84

The Relative Strength (RS) Rating for Gilead Sciences entered a new percentile Friday, with a rise from 78 to 84.

As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.

IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history shows that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves.

See How IBD Helps You Make More Money In Stocks

Gilead Sciences is working on a long consolidation with a 74.22 buy point. See if the stock can continue to move up and clear the breakout price in heavy trade.

Gilead Sciences reported -13% earnings growth in its most recent report. Revenue increased 1%.

The company earns the No. 54 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab and Vertex Pharmaceuticals are also among the group's highest-rated stocks.

​Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.